Less than one in 10 individuals that would benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it publishes its initial recommendations on the therapies.
Given more than one billion individuals worldwide currently classified as obese, it is urging more widespread and fairer availability to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The latest guidance recognises that excess weight is a lifelong illness that can be addressed with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant hurdles to broad access to the injections that can help people shift substantial body mass, says the organization.
Weight-Loss Drug Scarcity
Despite the current best projected case, the manufacturing of these medications might only reach approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.
The recommendation calls on countries and companies to increase availability, through measures including patent sharing.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026.
How Weight-Loss Jabs Operate
The injections imitate a natural hormone to slow digestion, curb appetite and boost satiety so people consume fewer calories.
People usually begin shedding pounds within a few weeks of starting on the regular doses.
Studies suggests patients may regain a significant portion within a year of stopping the treatment, because their usual hunger come back.
Being carrying excess weight elevates your likelihood for contracting diseases, such as type 2 diabetes, heart disease, stroke, and some malignancies.
Excess weight affects individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the WHO.
